HRP20250747T1 - Spojevi namijenjeni upotrebi u liječenju poremećaja hiperaktivnosti i nedostatka pažnje - Google Patents
Spojevi namijenjeni upotrebi u liječenju poremećaja hiperaktivnosti i nedostatka pažnjeInfo
- Publication number
- HRP20250747T1 HRP20250747T1 HRP20250747TT HRP20250747T HRP20250747T1 HR P20250747 T1 HRP20250747 T1 HR P20250747T1 HR P20250747T T HRP20250747T T HR P20250747TT HR P20250747 T HRP20250747 T HR P20250747T HR P20250747 T1 HRP20250747 T1 HR P20250747T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- adhd
- use according
- administered
- interventions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2101292.7A GB202101292D0 (en) | 2021-01-29 | 2021-01-29 | Novel treatments |
| GBGB2101291.9A GB202101291D0 (en) | 2021-01-29 | 2021-01-29 | Novel treatments |
| GBGB2101296.8A GB202101296D0 (en) | 2021-01-29 | 2021-01-29 | Novel treatments |
| EP22708379.7A EP4284356B1 (en) | 2021-01-29 | 2022-01-28 | Compounds for use in the treatment of attention deficit hyperactivity disorder |
| PCT/EP2022/052142 WO2022162199A2 (en) | 2021-01-29 | 2022-01-28 | Novel treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20250747T1 true HRP20250747T1 (hr) | 2025-08-15 |
Family
ID=80682355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20250747TT HRP20250747T1 (hr) | 2021-01-29 | 2022-01-28 | Spojevi namijenjeni upotrebi u liječenju poremećaja hiperaktivnosti i nedostatka pažnje |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240130995A1 (https=) |
| EP (1) | EP4284356B1 (https=) |
| JP (1) | JP2024508372A (https=) |
| AU (1) | AU2022215118A1 (https=) |
| CA (1) | CA3206935A1 (https=) |
| ES (1) | ES3038949T3 (https=) |
| HR (1) | HRP20250747T1 (https=) |
| HU (1) | HUE071725T2 (https=) |
| PL (1) | PL4284356T3 (https=) |
| RS (1) | RS66934B1 (https=) |
| SM (1) | SMT202500238T1 (https=) |
| WO (1) | WO2022162199A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025093748A1 (en) * | 2023-11-03 | 2025-05-08 | 3Z Pharmaceuticals | Use of a calcium channel blocker in the treatment of adhd |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1030672A1 (en) * | 1997-11-19 | 2000-08-30 | Merck & Co., Inc. | Method for treating attention deficit disorder |
| US20040002500A1 (en) * | 2002-06-28 | 2004-01-01 | Fabre Kramer Pharmaceutical, Inc. | Methods for treating attention deficit disorder |
| CA2546395A1 (en) * | 2003-11-21 | 2005-06-09 | Memory Pharmaceutical Corporation | Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors |
| EP1609783A1 (en) * | 2004-06-17 | 2005-12-28 | Neuropharma S.A.U. | Marine compounds with calcium channel blocking properties for Alzheimer's disease treatment |
| US20080226715A1 (en) * | 2007-03-16 | 2008-09-18 | Albert Cha | Therapeutic compositions and methods |
| WO2011100659A2 (en) * | 2010-02-12 | 2011-08-18 | Kitov Pharmaceutical Ltd. | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
| PL2895507T3 (pl) * | 2012-09-11 | 2019-04-30 | Inst Catalana De Recerca I Estudis Avancats | Sposób diagnostyczny do wykrywania choroby autoimmunologicznej oraz przedmioty z nim związane |
| WO2014133329A1 (ko) * | 2013-02-27 | 2014-09-04 | 에스케이케미칼 주식회사 | 관절염 치료용 복합 제제 |
| KR20140135676A (ko) * | 2014-10-02 | 2014-11-26 | 한국과학기술원 | 주의력 결핍 과잉 행동 모델 마우스, 상기 모델 마우스를 이용한 집중력 장애 질병 예방 및 완화 효과 검증 방법, 및 비특이적 ｔ―타입 칼슘 억제제를 함유하는 집중력 장애 질병 예방 및 치료용 조성물 |
| JP2021500416A (ja) * | 2017-10-27 | 2021-01-07 | エステベ ファーマスーティカルズ，ソシエダッド アノニマ | 疼痛及び疼痛関連状態を治療するための新規アルコキシアミノ誘導体 |
| WO2020120606A1 (en) * | 2018-12-12 | 2020-06-18 | Esteve Pharmaceuticals, S.A. | New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions |
-
2022
- 2022-01-28 SM SM20250238T patent/SMT202500238T1/it unknown
- 2022-01-28 RS RS20250624A patent/RS66934B1/sr unknown
- 2022-01-28 JP JP2023546027A patent/JP2024508372A/ja active Pending
- 2022-01-28 HU HUE22708379A patent/HUE071725T2/hu unknown
- 2022-01-28 AU AU2022215118A patent/AU2022215118A1/en active Pending
- 2022-01-28 CA CA3206935A patent/CA3206935A1/en active Pending
- 2022-01-28 WO PCT/EP2022/052142 patent/WO2022162199A2/en not_active Ceased
- 2022-01-28 US US18/274,945 patent/US20240130995A1/en active Pending
- 2022-01-28 PL PL22708379.7T patent/PL4284356T3/pl unknown
- 2022-01-28 ES ES22708379T patent/ES3038949T3/es active Active
- 2022-01-28 EP EP22708379.7A patent/EP4284356B1/en active Active
- 2022-01-28 HR HRP20250747TT patent/HRP20250747T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3206935A1 (en) | 2022-08-04 |
| SMT202500238T1 (it) | 2025-07-22 |
| PL4284356T3 (pl) | 2025-07-28 |
| JP2024508372A (ja) | 2024-02-27 |
| WO2022162199A2 (en) | 2022-08-04 |
| EP4284356A2 (en) | 2023-12-06 |
| HUE071725T2 (hu) | 2025-09-28 |
| AU2022215118A1 (en) | 2023-08-17 |
| AU2022215118A9 (en) | 2024-05-16 |
| EP4284356B1 (en) | 2025-04-02 |
| EP4284356C0 (en) | 2025-04-02 |
| RS66934B1 (sr) | 2025-07-31 |
| US20240130995A1 (en) | 2024-04-25 |
| WO2022162199A3 (en) | 2022-09-15 |
| ES3038949T3 (en) | 2025-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Donn et al. | Prevention of intraventricular haemorrhage in preterm infants by phenobarbitone: a controlled trial | |
| ES2542892T3 (es) | Terapia de combinación para el tratamiento de hipertensión asociada con la obesidad | |
| PT1463528E (pt) | Inibidores selectivos da recaptação da serotonina e da norepinefrina para tratamento de síndrome de fibromialgia, síndrome da fadiga crónica e dor | |
| MX2007007416A (es) | Derivados de 1-aminociclohexano para el tratamiento de esclerosis multiple, inestabilidad emocional y afectacion pseudobulbar. | |
| LÉAN et al. | Beneficial effects of serotonin precursors in postanoxic action myoclonus | |
| CN106999467A (zh) | 治疗认知减退的方法 | |
| JP2017510607A5 (https=) | ||
| HRP20250747T1 (hr) | Spojevi namijenjeni upotrebi u liječenju poremećaja hiperaktivnosti i nedostatka pažnje | |
| Mueller et al. | Cocaine | |
| JP2025504984A5 (https=) | ||
| Gilligan et al. | Amantadine hydrochloride in the treatment of Parkinson's disease | |
| JP2024508372A5 (https=) | ||
| Falls et al. | Serotonin syndrome in a patient on tramadol, bupropion, trazodone, and oxycodone | |
| WO2010126527A1 (en) | Methods of treating cns disorders | |
| Koga et al. | Pain in Miller Fisher syndrome | |
| ES2964790T3 (es) | (2S)-1-[4-(3,4-Diclorofenil)piperidin-1-il]-3-[2-(5-metil-l,3,4-oxadiazol-2-il)benzo[b]furano-4-iloxi]propan-2-ol o su metabolito para tratar trastornos de ansiedad | |
| EP3854391B1 (en) | Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder | |
| JPS63500796A (ja) | アミノシクロアルキルアミドの抗不整脈剤用途 | |
| LITMAN | Heatstroke in parkinsonism | |
| Farag et al. | Methamphetamine poisoning after" plugging" intentional recreational rectal use | |
| Lorimer et al. | Cardiovascular disease | |
| CN105012233B (zh) | 一种含有普鲁卡因的用于分娩的组合物及制备方法 | |
| JP2006515610A (ja) | めまいのための複合製剤 | |
| RU2796295C2 (ru) | Карбаматное соединение и применение включающей его композиции для профилактики, облегчения или лечения острого стрессового расстройства или посттравматического стрессового расстройства | |
| KR101758949B1 (ko) | 활성 성분으로 ｌ-카르니틴 또는 프로피오닐 ｌ-카르니틴을 포함하는, 만성 정맥 기능부전의 예방 또는 치료용 복합 조성물 |